Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17:147–67.

Article  PubMed  Google Scholar 

Maus MV. A decade of CAR T-cell evolution. Nat Cancer. 2022;3:270–1.

Article  PubMed  Google Scholar 

Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T-cell survival in the tumor. Nat Biotechnol. 2018;36:346–51.

Article  PubMed  CAS  Google Scholar 

Tian Y, Li Y, Shao Y, Zhang Y. Gene modification strategies for next-generation CAR T cells against solid cancers. J Hematol Oncol. 2020;13:54.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhao Z, Xiao X, Saw PE, Wu W, Huang H, Chen J, et al. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. Sci China Life Sci. 2020;63:180–205.

Article  PubMed  CAS  Google Scholar 

Huang J, Zhang L, Wan D, Zhou L, Zheng S, Lin S, et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct Target Ther. 2021;6:153.

Article  PubMed  PubMed Central  Google Scholar 

Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168:724–40.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sterner RC, Sterner RM. CAR-T-cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.

Article  PubMed  PubMed Central  Google Scholar 

Xu M, Zhang T, Xia R, Wei Y, Wei X. Targeting the tumor stroma for cancer therapy. Mol Cancer. 2022;21:208.

Article  PubMed  PubMed Central  Google Scholar 

Gordon-Weeks A, Yuzhalin AE. Cancer Extracellular Matrix Proteins Regulate Tumour Immunity. Cancers (Basel). 2020;12:3331.

Kolesnikoff N, Chen CH, Samuel MS. Interrelationships between the extracellular matrix and the immune microenvironment that govern epithelial tumor progression. Clin Sci (Lond). 2022;136:361–77.

Article  PubMed  CAS  Google Scholar 

Kuczek DE, Larsen A, Thorseth ML, Carretta M, Kalvisa A, Siersbæk MS, et al. Collagen density regulates the activity of tumor-infiltrating T cells. J Immunother Cancer. 2019;7:68.

Article  PubMed  PubMed Central  Google Scholar 

Nicolas-Boluda A, Vaquero J, Vimeux L, Guilbert T, Barrin S, Kantari-Mimoun C, et al. Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. Elife. 2021;10:e58688.

Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. 2014;2:154–66.

Article  PubMed  CAS  Google Scholar 

Lee IK, Noguera-Ortega E, Xiao Z, Todd L, Scholler J, Song D, et al. Monitoring therapeutic response to Anti-FAP CAR T cells using [18F]AlF-FAPI-74. Clin Cancer Res. 2022;28:5330–42.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liu Y, Sun Y, Wang P, Li S, Dong Y, Zhou M, et al. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer. J Transl Med. 2023;21:255.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210:1125–35.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21:524–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ramanathan RK, McDonough SL, Philip PA, Hingorani SR, Lacy J, Kortmansky JS, et al. Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J Clin Oncol. 2019;37:1062–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, Thomson M, et al. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell. 2016;164:780–91.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Roybal KT, Williams JZ, Morsut L, Rupp LJ, Kolinko I, Choe JH, et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell. 2016;167:419–32.e416.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang G, Zhang Z, Zhong K, Wang Z, Yang N, Tang X, et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T-cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Mol Ther. 2023;31:134–53.

Article  PubMed  CAS  Google Scholar 

Dutta D, Heo I, Clevers H. Disease modeling in stem cell-derived 3D organoid systems. Trends Mol Med. 2017;23:393–410.

Article  PubMed  CAS  Google Scholar 

Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumor microenvironment. Nat Rev Drug Discov. 2021;20:531–50.

Article  PubMed  CAS  Google Scholar 

Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418–29.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wen B, Xu LY, Li EM. LOXL2 in cancer: regulation, downstream effectors and novel roles. Biochim Biophys Acta Rev Cancer. 2020;1874:188435.

Article  PubMed  CAS  Google Scholar 

Lampi MC, Reinhart-King CA. Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials. Sci Transl Med. 2018;10:eaao0475.

Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463–516.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010;20:161–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhang W, Liu L, Su H, Liu Q, Shen J, Dai H, et al. Chimeric antigen receptor macrophage therapy for breast tumors mediated by targeting the tumor extracellular matrix. Br J Cancer. 2019;121:837–45.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chiriaco C, Donini C, Cortese M, Ughetto S, Modica C, Martinelli I, et al. Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy. J Exp Clin Cancer Res. 2022;41:309.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hu J, Wang Z, Liao C, Chen Z, Kang F, Lin C, et al. Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability. Front Immunol. 2022;13:958960.

Article